The company said it will use the financing to support the commercialization of its automated biological testing platform for academic and clinical research.
Thrive Earlier Detection is banking on targeted detection of frequent cancer mutations, coupled with protein markers, while competitors turn to genome-wide approaches.
The multi-analyte assay could screen for cancers that currently lack early-stage detection methods, including ovarian, liver, stomach, pancreatic, and esophageal cancers.
The German firm grew revenues to €5.3 million for the first nine months of the year from €976,000 a year ago, but its net loss expanded 48 percent year over year.
The Economist reports that it is increasingly easier to analyze the metabolites people give off, potentially revealing personal information about them.
